Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Papamichail

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Stem Cells and Development|January 6, 2011
Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cellsOlga Katsara, Louisa G Mahaira, Eleni G Iliopoulou, et al.
Stem Cells and Development|June 11, 2014
IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylasesLouisa G Mahaira, Olga Katsara, Efthimia Pappou, et al.
The Journal of Biological Chemistry|March 17, 2005
CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cellsPanayotis Ioannidis, Louisa G Mahaira, Sonia A Perez, et al.
Cancer Immunology, Immunotherapy : CII|January 25, 2002
HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clonesSonia A Perez, Panagiota A Sotiropoulou, Nectaria N Sotiriadou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2010
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancerSonia A Perez, Nikoletta L Kallinteris, Stratos Bisias, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2006
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumorsNectaria N Sotiriadou, Nikoletta L Kallinteris, Angelos D Gritzapis, et al.
Blood|March 10, 2005
A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survivalSonia A Perez, Louisa G Mahaira, Fillio J Demirtzoglou, et al.
Blood|December 31, 2002
A novel myeloid-like NK cell progenitor in human umbilical cord bloodSonia A Perez, Panagiota A Sotiropoulou, Dimitra G Gkika, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patientsSonia A Perez, Michael V Karamouzis, Dimosthenes V Skarlos, et al.
Oncotarget|September 3, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrenceElizabeth A Mittendorf, Alexandros Ardavanis, Jennifer K Litton, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Stem Cells and Development|January 6, 2011
Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cellsOlga Katsara, Louisa G Mahaira, Eleni G Iliopoulou, et al.
Stem Cells and Development|June 11, 2014
IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylasesLouisa G Mahaira, Olga Katsara, Efthimia Pappou, et al.
The Journal of Biological Chemistry|March 17, 2005
CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cellsPanayotis Ioannidis, Louisa G Mahaira, Sonia A Perez, et al.
Cancer Immunology, Immunotherapy : CII|January 25, 2002
HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clonesSonia A Perez, Panagiota A Sotiropoulou, Nectaria N Sotiriadou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2010
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancerSonia A Perez, Nikoletta L Kallinteris, Stratos Bisias, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2006
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumorsNectaria N Sotiriadou, Nikoletta L Kallinteris, Angelos D Gritzapis, et al.
Blood|March 10, 2005
A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survivalSonia A Perez, Louisa G Mahaira, Fillio J Demirtzoglou, et al.
Blood|December 31, 2002
A novel myeloid-like NK cell progenitor in human umbilical cord bloodSonia A Perez, Panagiota A Sotiropoulou, Dimitra G Gkika, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patientsSonia A Perez, Michael V Karamouzis, Dimosthenes V Skarlos, et al.
Oncotarget|September 3, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrenceElizabeth A Mittendorf, Alexandros Ardavanis, Jennifer K Litton, et al.
Pageof 7